Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents

Cancer Chemotherapy and Pharmacology

Volumn 41, Issue 6, 1998, Pages 485-490

  Coggins, Claire A ^a   Elion, Gertrude B ^a   Houghton, Peter J ^b   Hare, C Bradley ^a   Keir, Steve ^a   Colvin, O Michael ^a   Bigner, Darell D ^a   Friedman, Henry S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Alkylators; Ependymoma; Glioma; Irinotecan (CPT 11); Medulloblastoma

Indexed keywords

ALKYLATING AGENT; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CENTRAL NERVOUS SYSTEM TUMOR; CHILDHOOD CANCER; CONTROLLED STUDY; DRUG POTENTIATION; EPENDYMOMA; FEMALE; GLIOMA; HOST; INTRAPERITONEAL DRUG ADMINISTRATION; LETHALITY; MALE; MEDULLOBLASTOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; BUSULFAN; CAMPTOTHECIN; CARMUSTINE; CHILD; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASES, TYPE I; DRUG COMBINATIONS; DRUG INTERACTIONS; ENZYME INHIBITORS; EPENDYMOMA; FEMALE; GLIOMA; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0031913229     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050771     Document Type: Article

References (10)

1. Bullard DE, Bigner DD (1979) The hetcrotransplantation of human craniopharyngiomas in athymic "nude" mice. Neurosurgery 4: 308
2. Colvin OM, Chabner BA (1990) Alkylating agents. In: Chabner BA, Collins JM (eds) Cancer chemotherapy. Principles and practice. J.B. Lippincott Co., Philadelphia. p 276
3. Friedman HS, Schold SC Jr, Bigner DD (1986) Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice. Cancer Res 46: 224
4. Friedman HS, Houghton PJ, Schold SC, Keir S, Bigner DD (1994) Activity of 9-dimethylaminomethyl-10-hydroxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 34: 171
5. Hall AG, Tilby MJ (1992) Mechanism of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev 6: 165
6. Hare CB, Elion GB, Houghton PJ, Houghton JA, Keir S, Marcelli SL, Bigner DD, Friedman HS (1997) Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10(4-[1-piperidino]-l-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 39: 187
7. Rideout DC, Chou TC (1991) Synergism, antagonism, and potentiation in chemotherapy: an overview. In: Chao TC and Rideout DC (eds) Synergism and antagonism in chemotherapy. Academic Press, San Diego, p 3
8. Shiminski-Maher T, Wisoff JH (1995) Pediatric brain tumors. Crit Care Nurs Clin North Am 7: 159
9. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH (1993) The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85: 272
10. Von Hoff DD, Burns HA, Eckardt J, Rothenberg M, Fields SM, Chen SF, Kuhn JG (1994) Preclinical and phase I trials of topoisomerase I inhibitors. Cancer Chemother Pharmacol 34: S43